American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting最新文献

{"title":"Is Less More? Maximizing Outcomes by Tailoring Treatments to Patients: Oncofertility and Oncomenopause.","authors":"Janice S Kwon, Marie Plante, Martha Hickey, Annabelle Huguenin, Sarah Hmaidan, Terri Lynn Woodard","doi":"10.1200/EDBK-25-481126","DOIUrl":"https://doi.org/10.1200/EDBK-25-481126","url":null,"abstract":"<p><p>Notable advances have been made in improving survival outcomes in various cancers, but some have incurred undesirable costs and effects to patients with respect to fertility and menopause. Patients are living longer with cancer, and patient reported outcomes are influencing decision-making by individuals and their health care providers. It is essential to evaluate existing standards of care on an ongoing basis and prioritize quality of life and long-term survivorship, particularly for interventions in early-stage cancers and risk-reducing strategies that often yield long-term life expectancy.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e481126"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver-Directed Therapies in Colorectal Cancer: Old Hats and New Tricks.","authors":"Nicholas Hornstein, Jacob Levenson, Toshihiro Nakayama, Kazunari Sasaki, Federico Aucejo, Roberto Hernandez-Alejandro, Riad Salem, Eric D Miller, Sepideh Gholami","doi":"10.1200/EDBK-25-473598","DOIUrl":"https://doi.org/10.1200/EDBK-25-473598","url":null,"abstract":"<p><p>Resection of liver metastases is considered the only treatment with curative potential for patients with metastatic colorectal cancer to the liver (CRLM). However, only a minority of patients with CRLM are eligible for up-front resection of liver metastases. Despite advances in systemic chemotherapy, long-term survival is rare without resection of liver metastases. This highlights the unmet need for alternative localized treatment options for patients with unresectable colorectal liver metastases (uCRLM). Liver-directed therapies include hepatic artery infusion pump (HAIP) therapy and nonsurgical locoregional approaches including image-guided ablation, Y90 radioembolization (TARE), and stereotactic body radiation therapy. More recently, emergent data support the use of liver transplantation (LT) in select patients with uCRLM. In this chapter, we review the data for various liver-directed therapies revolutionizing the treatment approach and improving clinical outcomes for patients with uCRLM.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473598"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144286706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis and Educational Overview of the ASCO-Society of Integrative Oncology Guidelines: On the Path to Implementation.","authors":"Krisstina Gowin, Eugene R Ahn, Ana Maria Lopez","doi":"10.1200/EDBK-25-471830","DOIUrl":"10.1200/EDBK-25-471830","url":null,"abstract":"<p><p>Cancer care is rapidly changing. Advances in treatments therapeutics, such as gene and immunotherapies, have revolutionized patient outcomes and given new hope to survivors and cosurvivors. Despite these advances, disease- and treatment-related symptoms remain prevalent; impact quality of life, treatment tolerance, and clinical outcomes; and may persist for years after the diagnosis. Integrative oncology (IO) has been defined as a patient-centered, evidence-informed field of cancer care that uses mind and body practices, natural products, and/or lifestyle modifications from different traditions alongside conventional cancer treatments. IO aims to optimize health, quality of life, and clinical outcomes across the cancer care continuum and to empower people to prevent cancer and become active participants before, during, and beyond cancer treatment. Guidelines by The Society of Integrative Oncology (SIO) with subsequent endorsement by ASCO Expert Panel have been developed for cancer pain management, depression and anxiety, and fatigue. This set of evidence-based IO guidelines provide a new set of supportive care tools for cancer care. As most National Cancer Institute-designated comprehensive cancer centers now offer IO care, the interest in nonpharmacologic care has increased for both patients and health professionals. This manuscript will review the evidence-based ASCO-SIO guidelines, discuss strategies for their successful implementation within standard-of-care treatment models, and review nonjudgmental communication approaches to foster collaborative integrative care.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e471830"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144508753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Global Oncology: Tackling Disparities and Promoting Innovations in Low- and Middle-Income Countries.","authors":"Regina Barragan-Carrillo, Fredrick Chite Asirwa, Rodrigo Dienstmann, Dinesh Pendhakar, Erika Ruiz-Garcia","doi":"10.1200/EDBK-25-473930CX1","DOIUrl":"https://doi.org/10.1200/EDBK-25-473930CX1","url":null,"abstract":"","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473930CX1"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Drugs, New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies.","authors":"Alexis LeVee, Alana Deutsh, Ethan S Lindgren, Rongshan Yan, Heather Moore, Neel D Pasricha, Jonathan Leventhal, Susan Dent, Hope S Rugo","doi":"10.1200/EDBK-25-473384","DOIUrl":"https://doi.org/10.1200/EDBK-25-473384","url":null,"abstract":"<p><p>With the rapid introduction of novel breast cancer therapies, recognizing and managing side effects is essential to maintain adherence and improve outcomes. As novel oral endocrine therapies and combination strategies including targeted agents have prolonged progression and in some cases disease-free survival, early recognition and appropriate management of these toxicities is critical to optimize quality of life. Dermatologic adverse events are frequently associated with novel breast cancer therapies including immune checkpoint inhibitors (ICIs), targeted therapies, and antibody-drug conjugates (ADCs). These include various rashes, stomatitis, and alopecia, necessitating multidisciplinary dermatologic intervention to allow for prompt management of cutaneous toxicities and continuation of oncologic therapy. Targeted breast cancer therapies, including ADCs, can also induce ocular adverse events (OAEs), such as corneal pseudomicrocysts which lead to blurry vision and eye pain. Current preventative therapies have had limited success for these OAEs, necessitating dose interruptions. Although anthracycline-based chemotherapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy are associated with an increased risk of heart failure and left ventricular (LV) dysfunction, novel breast cancer therapies including ADCs, HER2 tyrosine kinase inhibitors, cyclin-dependent kinase 4 and 6 inhibitors, ICIs, and oral selective estrogen receptor degrader are also associated with an increased risk of LV dysfunction, heart failure, corrected QT prolongation, myocarditis, and bradycardia. This review provides a comprehensive overview of novel and emerging breast cancer therapy toxicities, with suggested management strategies to prevent and mitigate these adverse events. Through a multidisciplinary approach involving preventative strategies, monitoring, proactive interventions, providers can minimize symptom burden and improve patient adherence, ultimately improving breast cancer outcomes.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473384"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144601829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras.","authors":"Vivek Subbiah, Megan Othus, Jim Palma, Branko Cuglievan, Razelle Kurzrock","doi":"10.1200/EDBK-25-100051","DOIUrl":"https://doi.org/10.1200/EDBK-25-100051","url":null,"abstract":"<p><p>The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the National Cancer Institute, occur in fewer than 150 cases per million people each year, yet they collectively represent a significant portion of all cancer diagnoses. Because of their infrequency, these cancers pose distinct challenges for clinical trials, including limited patient populations, geographical dispersion, and a general lack of awareness of treatment options. Economic limitations further complicate drug development, making initiatives such as the Orphan Drug Act essential for incentivizing research. The advent of next-generation sequencing (NGS) and precision medicine has been instrumental in identifying actionable genetic alterations in parallel with an explosion in the development of genomically targeted therapies, immunotherapies, and antibody drug conjugates. Advances in clinical NGS, precision medicine, and tumor-agnostic therapies have become central to the progress in rare cancer research. The development and approval of tumor-agnostic drugs, such as BRAF, NTRK, and RET inhibitors, and immunotherapy for mismatch repair deficient/microsatellite instability-high status cancers highlight the potential of personalized treatments across diverse cancer types and across the age spectrum. Collaborative trials from cooperative groups including SWOG DART, ASCO TAPUR, NCI-MATCH, pediatric COG-match, DRUP, IMPRESS, and innovative registrational basket and platform trials (eg, VE-Basket, ROAR, LIBRETTO-001, ARROW), along with patient advocacy group-run trials like TRACK, are enhancing access to clinical trials. In addition, artificial intelligence has the potential to improve the trial matching process. An integrated approach, combining these innovations in collaboration with multiple stakeholders, is crucial for advancing rare cancer research, offering hope for better patient outcomes and quality of life.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e100051"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.","authors":"Teja Voruganti, Rosalyn Marar, Benjamin Bleiberg, Edoardo Garbo, Biagio Ricciuti, Kaushal Parikh, Charu Aggarwal","doi":"10.1200/EDBK-25-472804","DOIUrl":"https://doi.org/10.1200/EDBK-25-472804","url":null,"abstract":"<p><p>Perioperative therapy has become a critical component in the management of resectable non-small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is standard in metastatic NSCLC, its incorporation into early-stage disease remains essential for guiding treatment decisions. Reflex molecular testing pathways are necessary to optimize tissue utilization and ensure timely results. However, liquid biopsies, although valuable in advanced disease, have limited sensitivity in early-stage NSCLC, reinforcing the need for tissue-based next-generation sequencing. Targeted therapies have revolutionized treatment for oncogene-driven NSCLC, with adjuvant osimertinib now standard for EGFR-mutant disease and ongoing investigations into ALK tyrosine kinase inhibitors (TKIs). However, unanswered questions remain regarding the inclusion of perioperative TKI therapy, the role of molecular residual disease assessment, and whether specific TKIs offer greater benefit for high-risk subgroups. The role of immunotherapy (IO) in oncogene-driven NSCLC remains controversial. Although perioperative chemo-IO has demonstrated survival benefits in unselected NSCLC, its efficacy in EGFR, ALK, and other actionable alterations is unclear. Tumors harboring KRAS and BRAF mutations may respond better because of a more immune-inflamed microenvironment, and remains an active area of investigation. As the landscape of perioperative therapy continues to evolve, ongoing trials will help define the optimal integration of targeted therapies and IO in oncogene-driven NSCLC. Addressing these unanswered questions will be crucial in refining treatment strategies and improving patient outcomes.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472804"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pegylated Interferons: Still a Major Player for the Treatment of Myeloproliferative Neoplasms.","authors":"Michael Daunov, Rebecca B Klisovic","doi":"10.1200/EDBK-25-473912","DOIUrl":"https://doi.org/10.1200/EDBK-25-473912","url":null,"abstract":"<p><p>Over the past 35 years, interferons have been explored in various formulations for the management of Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), such as essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis, and remain a key tool in caring for patients with these diseases. These agents are excellent cytoreductive agents with high rates of hematologic response, are helpful in symptom management, and have a long track record of safety and manageable toxicities. More recently, they have shown promise in sustaining responses over many years, with associated reductions in driver mutations (<i>JAK2, MPL, CALR</i>) of these diseases, particularly in PV and ET. Since reductions in molecular mutant allele burden have been correlated with several response outcomes such as reductions in both thrombotic risk and disease progression, there is emerging proof that interferons may offer disease-modifying activity. These long-term benefits and their use as the preferred agent in young pregnant women who need cytoreduction make interferons often the first choice in young adult population who harbor a lifetime risk of progression. Looking forward, the prospect of sustained treatment-free responses, like chronic myeloid leukemia after deep molecular response, and normal life expectancy may also be on the frontier. Despite relative rookies such as JAK inhibitors in the MPN landscape, the veteran in the game, interferon, remains a key player.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473912"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast Cancer.","authors":"Jimmitti Teysir, Maxwell R Lloyd, Samer Alkassis, Rena D Callahan, Ricki Fairley, Seth A Wander, Aditya Bardia, Komal L Jhaveri","doi":"10.1200/EDBK-25-473372","DOIUrl":"10.1200/EDBK-25-473372","url":null,"abstract":"<p><p>CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor-positive metastatic breast cancer, offering demonstrable improvements in both progression-free survival and overall survival. However, resistance inevitably develops, and the optimal treatment sequencing after CDK4/6i progression remains undefined. Tumor heterogeneity and diverse resistance mechanisms-including alterations in <i>ESR1</i> and <i>PIK3CA</i>-complicate treatment decisions in the post-CDK4/6i setting. Genomic profiling has helped to characterize these and other clinically relevant alterations, uncovering new avenues for therapeutic intervention. Building on these insights, a growing number of novel endocrine agents, phosphoinositide-3-kinase/AKT pathway-targeted therapies, and antibody-drug conjugates (ADCs) have demonstrated efficacy in biomarker-selected populations and are reshaping the treatment landscape beyond CDK4/6i progression. This chapter reviews current standards of care, emerging therapeutic options, and evolving combination strategies across biomarker-defined subgroups. We also highlight how ongoing clinical trials and advances in molecular profiling are informing personalized approaches to overcome endocrine resistance and improve patient outcomes.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473372"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current and Future Directions of Immunotherapies in Multiple Myeloma.","authors":"Eden M D Biltibo, Malini Surapaneni, Samer Al Hadidi, Attaya Suvannasankha, Reena V Jayani-Kosarzycki","doi":"10.1200/EDBK-25-473316","DOIUrl":"https://doi.org/10.1200/EDBK-25-473316","url":null,"abstract":"<p><p>Treatment of multiple myeloma (MM) has evolved significantly over the past few decades. Up-front treatment options expanded from doublet regimens to triplets and now to quadruplets. Monoclonal antibodies have significantly contributed to this paradigm shift. Their incorporation into frontline regimens demonstrated improved survival outcomes irrespective of transplantation eligibility. Autologous hematopoietic stem-cell transplant (ASCT) remains standard in frontline consolidation therapy with recent expansion of eligibility, including older adults and patients with renal failure. The growing understanding of physiologic age and frailty, as well as improvements in supportive care, has made this possible. Bispecific T-cell engager (BiTE) antibodies are heralding a new age of treatment of MM with high response rates in patients with relapsed or refractory MM. With the impressive responses seen, these treatments are being studied in earlier lines of therapy and in combination with other therapies. With this rapidly evolving field of immunotherapy in MM, the goal of this review was to discuss the latest advances in MM treatment, focusing on up-front quadruplet therapy, the role of ASCT in the modern era, and the evolving role of BiTEs in up-front therapy.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473316"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}